Search





Search





Markets
/
Stocks
/
nasdaq-igc
/

IGC Pharma Inc

IGC

Add to Watchlist

0.286USD

-0.013-4.18%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

28.63MMarket Cap

LossP/E TTM



IGC Pharma Inc

0.286

-0.013-4.18%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of IGC Pharma Inc

Currency: USD Updated: 2026-05-15

Key Insights

IGC Pharma Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 163 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to remain stable.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

IGC Pharma Inc's Score

Industry at a Glance

Industry Ranking

163 / 382

Overall Ranking

298 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

IGC Pharma Inc Highlights

StrengthsRisks

IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.

Growing

The company is in a growing phase, with the latest annual income totaling USD 869.00K.

Undervalued

The company’s latest PE is -6.13, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 22.48M shares, increasing 11.30% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 919.64K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.84.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

4.000

Target Price

+1237.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of IGC Pharma Inc is 5.88, ranking 304 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 317.00K, representing a year-over-year decrease of 9.43%, while its net profit experienced a year-over-year decrease of 230.85%.

Score

Industry at a Glance

Previous score

5.88

Change



Financials

6.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.25

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

IGC Pharma Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of IGC Pharma Inc is 6.06, ranking 326 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.13, which is -82.93% below the recent high of -1.05 and -22.73% above the recent low of -7.52.

Score

Industry at a Glance

Previous score

6.06

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 163/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of IGC Pharma Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 3.62, with a high of 4.25 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

4.000

Target Price

+1298.60%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

IGC Pharma Inc

IGC

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of IGC Pharma Inc is 5.78, ranking 303 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.33 and the support level at 0.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.04

Change

-0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.011

Neutral

RSI(14)

39.781

Neutral

STOCH(KDJ)(9,3,3)

20.295

Sell

ATR(14)

0.016

Low Volatility

CCI(14)

-132.204

Sell

Williams %R

91.837

Oversold

TRIX(12,20)

0.058

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.296

Sell

MA10

0.307

Sell

MA20

0.317

Sell

MA50

0.296

Sell

MA100

0.289

Sell

MA200

0.332

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of IGC Pharma Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 22.76%, representing a quarter-over-quarter increase of 12.95%. The largest institutional shareholder is James Simons, holding a total of 483.98K shares, representing 0.49% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Bradbury Asset Management (Hong Kong) Limited

13.82M

Mukunda (Ram)

3.99M

-2.44%

Prins (Richard K)

1.37M

+7.87%

Grimaldi (Claudia)

1.13M

-4.22%

Moran (James P)

1.11M

Renaissance Technologies LLC

Star Investors

919.64K

-24.56%

Geode Capital Management, L.L.C.

860.48K

+0.94%

BlackRock Institutional Trust Company, N.A.

703.80K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of IGC Pharma Inc is 2.97, ranking 173 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.